摘要
Endovascular electrode arrays are a novel form of intracranial electrode delivery. Implanted stent electrode (Stentrode) devices are currently under investigation in patients with paralysis as a minimally invasive brain computer interface (BCI). Devices are chronically implantated in the superior sagittal sinus, connected by a transvenous lead via the internal jugular vein to an internal telemetry unit, which resides in a subclavicular pocket. Patient safety is the top priority in early feasibility studies of Stentrode devices, with a particular emphasis on avoiding thromboembolic events, namely in stent thrombosis. Whilst no implantation has yet resulted in serious adverse events, all foreign bodies in contact with the blood stream have a propensity to cause thrombosis. Thrombosis risk must be counterbalanced by the risk of pocket haematoma. The creation of a subclavicular pocket, whilst a standard procedure, inherently carries a risk of bleeding. This may progress to a clinically significant haematoma and an associated pocket infection, requiring an escalation in management. The current strategy for mitigating Stentrode-associated thrombosis risk involves the administration prophylactic dual antiplatelet therapy (DAPT), initiated 5 days before and extended for 3 months post-implantation, followed by a year-long continuation of aspirin monotherapy. This regimen is adapted from the prevailing preferred practice in SSS stenting for intracranial hypertension. However, the ideal antithrombotic regimen for intracranial venous sinus stenting is not well defined, and the additional risk associated with a subclavicular pocket has not yet been considered. We performed a systematic review and meta-analysis to capture each of these risks in the context of different antithrombotic agents, to help determine the optimal antithrombotic regime. We screened 3099 articles, resulting from searching 3 databases. Following blinded, independent screening, we extracted data from 96 articles, most of which reported on the risk of pocket haematoma. We assessed risk of bias using the mixed methods appraisal tool. We found a signficantly greater risk of pocket haematoma in the context of dual antiplatelet therapy, compared to anticoagulant therapies (OR 2.01, 1.07–3.77). Risk of pocket haematoma was lowest in the context of baseline DOAC therapy. There was no significant difference in mortality or pocket infection with the administration of different antithrombotic agents at the time of implantation. Regarding the risk of in-stent thrombosis in venous sinus stenting, only two cases were documented in the literature, and a meta-analysis could not be performed. Considering core haematological principles, antiplatelet agents may not be the most effective therapy in the context of venous stenting. These agents target platelet-driven thrombosis, however venous thrombi have a limited platelet component, and thrombogenesis is driven primarily by activation of the clotting cascade. Preclinical evidence supports this, by demonstrating aspirin and clopidogrel may fail to prevent venous stent thrombosis, whilst a factor Xa inhibitor completely inhibits thrombosis of venous stents. Altogether, our findings suggest that periprocedural DOAC may be the most appropriate antithrombotic therapy for the implantation of endovascular electrode arrays with a subclavicular device component. Disclosures J. Brannigan: 2; C; Synchron Inc,. A. McClanahan: 2; C; Synchron Inc.